Ticagrelor: Considerable added benefit for specific patients
Tuesday, October 11, 2011 - 11:03
in Health & Medicine
Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid (ASA) to avoid blood clots in patients with acute ischaemia of the cardiac muscle. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether ticagrelor offers advantages to patients with acute coronary syndrome (ACS) in comparison with conventional drugs. This is the first co-called "early benefit assessment" that IQWiG has performed on the basis of a dossier provided by the manufacturer, in accordance with the new legal regulations.